Objectives: In vitro and experimental studies in animals have established the anti-inflammatory effects of moxifloxacin. Cardiopulmonary bypass (CPB) leads to an inflammatory response. The aim of this study was to assess whether the inflammatory cytokine response to CPB is reduced with a perioperative antibiotic prophylaxis, either moxifloxacin or cefuroxime (the standard prophylaxis).
Introduction
In addition to its anti-infective properties, the fluoroquinolone moxifloxacin has immunomodulatory effects. 1 For example, in lipopolysaccharide (LPS)-stimulated monocytes and neutrophils, moxifloxacin inhibited the release of interleukins (ILs) and tumour necrosis factor-a (TNF-a). Cerebral inflammation was reduced in rats exposed to cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest (DHCA) at 15 -188C. 2 The inflammatory response to CPB has been well described. 3 It is triggered by the contact of blood with non-endothelial surfaces, ischaemia-reperfusion injury and endotoxaemia; a characteristic increase of ILs and TNF-a can be observed. 4, 5 Therefore, in this study we investigated whether there is an attenuation of the inflammatory cytokine response to CPB using either moxifloxacin as perioperative antibiotic prophylaxis or cefuroxime, the standard therapy.
Patients and methods
After approval by the local Ethics Committee and the regulatory authorities (EudraCT number 2006-000369-12), 30 patients scheduled for elective coronary artery bypass grafting (CABG) with CPB were selected. These patients were between 18 and 80 years old, gave their written informed consent and were enrolled in the study from February 2009 to December 2010. Exclusion criteria were: body mass index .30 kg/ m 2 ; ejection fraction ,50%; heart rate ,40 beats/min; symptomatic arrhythmia; intake of drugs that are associated with torsades de pointes and/or QT prolongation (e.g. amiodarone and tricyclic antidepressants); serum potassium ,3.8 or .5.0 mmol/L; serum creatinine .1.3 mg/dL; serum glutamic pyruvic transaminase (SGPT) .50 U/L; steroid therapy; hypersensitivity to fluoroquinolones, cephalosporins or other drugs with the possible need for steroid therapy; antibiotic therapy for infection diseases within the previous 2 weeks; tendinopathy due to former fluoroquinolone therapy; pregnancy; and nursing mothers.
For perioperative antibiotic prophylaxis, the patients randomly received either 400 mg of moxifloxacin intravenously after induction of anaesthesia (moxifloxacin group) or 3× 1.5 g of cefuroxime (after induction of anaesthesia, then 8 and 16 h thereafter) with an additional dose of 2.25 g in the CPB circuit (cefuroxime group). Antibiotic prophylaxis selection was not blinded. For unrestricted randomization, a list created by a random number generator was used. The whole implementation (generation of the random allocation sequence, enrolment and assignment of the participants to interventions) was done by the investigators. Two patients had to be excluded (one in each group): one operation was cancelled, and one patient had combined surgery (CABG and aortic valve replacement). No serious adverse events were observed.
All patients received a balanced anaesthetic. For extracorporeal circulation, a standardized CPB setup with a membrane oxygenator (Compactflo Evo w , Sorin, Mirandola, Italy) was used, with nonheparinized tubing and bovine heparin for anticoagulation. After crossclamping of the aorta, cold blood cardioplegia was used for cardiac arrest. CABG surgery was performed with mild hypothermia (328C).
As part of cardiac anaesthesia quality assurance, we recorded sex, age, height, weight, duration of CPB and aortic cross-clamping (AoX), need for catecholamine therapy after CPB (none, low or high dose), and rethoracotomy for any reason within the first 24 h. Low dose catecholamine therapy was defined as dopamine ≤5 mg/kg/min and/or epinephrine ≤200 mg/h and/or norepinephrine ≤500 mg/h; high dose was defined as levels above these.
Blood samples to determine the concentrations of IL-6, IL-8, IL-10 and TNF-a were obtained before induction of anaesthesia, 30 min after the antibiotic had been given, at the beginning of CPB, at the end of CPB, 30, 120 and 240 min after the end of CPB, and 24 h after the antibiotic had been given. The cytokines were measured using a solid-phase, enzyme-labelled chemiluminescent sequential immunometric assay (Immulite w , Siemens Healthcare Diagnostics, Eschborn, Germany). The lower limits of detection were 2 (IL-6), 4 (TNF-a) and 5 pg/mL (IL-8 and IL-10), respectively. For data evaluation, values below the detection limit were set to 0.
The difference in IL-6 concentration at 240 min after the end of CPB between the moxifloxacin and the cefuroxime groups was the primary outcome variable. Referring to a former study, 4 a total sample size of 28 was necessary to detect a mean difference of 100 pg/mL (s within each group 100 pg/mL), a of 0.05 and a power of 0.8 (GPOWER for MS-DOS, Franz Faul & Edgar Erdfelder, Bonn, Germany). All other differences in the cytokine concentrations between and within both groups were considered as secondary outcomes. Between group comparisons were performed with Fisher's exact tests (sex and need for rethoracotomy), Freeman-Halton test (need for catecholamine therapy after CPB) and Student's t-tests for normally distributed data (patient characteristics and perioperative data), and Mann-Whitney U-tests for nonnormally distributed data (IL-6, IL-8, IL-10, TNF-a). The Wilcoxon test was used for the within-group comparisons of cytokine concentrations. P,0.05 was considered significant, and the SPSS for Windows software package v17.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
Results
The patient characteristics and perioperative data are summarized in Table 1 . There was a statistically significant continuous Low dose, dopamine ≤5 mg/kg/min and/or epinephrine ≤200 mg/h and/or norepinephrine ≤500 mg/h; high dose, above these levels. 1 -82.1) and 36.4 (14.4 -80. 3) pg/mL] were reached at the end of CPB. There was no time at which the IL or TNF-a concentration was statistically significantly lower in the moxifloxacin group compared with the cefuroxime group. The P value for the primary endpoint (IL-6: 240 min after CPB) was 0.323.
Discussion
Despite its well-established immunomodulatory properties, moxifloxacin did not prevent continuous increase in cytokines after CPB, nor did it produce statistically significantly lower concentrations than cefuroxime.
The immunomodulatory effects of fluoroquinolones depend on cell type, co-stimulation, stimulant, drug concentration and type of fluoroquinolone.
1 For example, moxifloxacin inhibits the secretion of ILs and TNF-a in monocytes stimulated with LPS, but not if pansorbin is used instead of LPS. In human bronchial epithelial cells 24 h incubation with 8 mg/L moxifloxacin, in contrast to cefuroxime, reduced spontaneous IL-8 release. 6 In the same study, the TNF-a-stimulated IL-8 release was reduced at a moxifloxacin concentrations of at least 4 mg/L. All these concentrations are higher than the maximum concentration that was observed (3.62 mg/L) after the recommended intravenous single daily dose (400 mg). 7 Recently, the influence of moxifloxacin on cerebral inflammation after CPB and DHCA was investigated in rats.
2 Moxifloxacin, 6×100 mg/kg every 2 h intraperitoneally, reduced the number of hippocampal neurons positive for inflammatory markers, such as TNF-a, nuclear factor-kB and cyclooxygenase 2. Unfortunately, CPB without DHCA was not investigated.
Clinical studies in patients on the immunomodulatory properties of moxifloxacin have focused on immunodepression after stroke. In the PANTHERIS trial, Harms and co-workers 8 investigated the influence of a preventive antibacterial therapy with moxifloxacin versus placebo on monocytic human leucocyte antigen (HLA)-DR expression, a marker of post-stroke immunodepression. Whereas in the entire group no significant difference in the time course of monocytic HLA-DR was observed, moxifloxacin prevented the decrease in monocytic HLA-DR expression (i.e. post-stroke immunodepression) in patients that suffered an infection relative to those who did not. In a later study the antiinflammatory effect of moxifloxacin, measured by the time courses of IL-6 and IL-10, was also seen only in patients with infections, and not in the entire group. 9 Thus, infections appear to play a crucial role for the clinically relevant anti-inflammatory properties of moxifloxacin. This is supported by a recently published in vitro study by Trautmann and co-workers. 10 They found lower endotoxin release from Escherichia coli and Bacteroides fragilis (and lower TNF-a release in response to endotoxin) with moxifloxacin compared to ceftazidime. These effects were observed at antibiotic concentrations as low as twice the MIC.
With regard to the limitations of our investigation, we found much greater variability in the inflammatory cytokine response to CPB in comparison with the former study by Tassani and co--workers. 4 The reason for this is unclear because this study was performed at the same institution (German Heart Centre Munich) under similar conditions. This greater variability reduces the power of our study, but it is in line with a recently published study dealing with CPB and inflammation. 5 For ethical reasons a placebo-controlled study was not possible, and the between-group comparisons had to be performed with cefuroxime, the standard antibiotic prophylaxis.
In conclusion, moxifloxacin failed to significantly attenuate inflammatory mediator release in the unique clinical situation of CPB. There are two possible reasons: firstly, contact activation, the major trigger during CPB, is different from the inflammatory pathways that are activated during infectious disease; and secondly, a single intravenous dose of 400 mg of moxifloxacin may not lead to plasma and intracellular concentrations that are high enough to have significant antiinflammatory effects.
